Abstract 56P
Background
Introduction: The treatment landscape for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) has significantly evolved in Korea. However, large-scale multicenter studies analyzing clinicopathologic data and treatment outcomes are lacking. This study establishes a prospective and retrospective multicenter observational cohort to include all stages of EGFR-mutated NSCLC patients.
Methods
This study aims to enroll 2,000 patients with EGFR-mutated NSCLC from 40 institutions. Patient data, including demographics, smoking history, quality of life, pathological data, and treatment outcomes, are being collected, with follow-up until December 2026. The primary endpoints are disease-free survival in radically treated patients and progression-free survival for those receiving targeted therapy, chemotherapy, or combination therapy, according to disease stage. Secondary analyses include diagnostic methods for EGFR mutations, treatment outcomes, and metastatic patterns. The study also evaluates the safety and efficacy of lazertinib, a third-generation EGFR tyrosine kinase inhibitor approved for first- and second-line treatments.
Results
A total of 1,929 patients have been enrolled in the study based on eligibility and exclusion criteria, with a median age of 68 years (IQR: 61–76) and a median follow-up of 19 months (IQR: 12–27). Among the cohort, 59.9% were female, and 64.2% were never smokers. Stage distribution was as follows: Stage I (25.5%), Stage II (5.3%), Stage III (11.5%), and Stage IV (57.6%). Surgery was predominantly performed in early stages (95.3% in Stage I), while EGFR-TKI therapy was most common in Stage IV (97.6%). Advanced stages saw increased use of radiotherapy, concurrent chemoradiation therapy (CCRT), and chemotherapy.
Conclusions
This study provides critical insights into the epidemiology, progression, and treatment outcomes of EGFR-mutated NSCLC in Korea. Findings from the study will enhance the understanding of EGFR-mutated NSCLC and support the development of personalized treatment strategies.
Legal entity responsible for the study
Supported by Yuhan.
Funding
Yuhan.
Disclosure
All authors have declared no conflicts of interest.